Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGCG | Q16739 | 13/20 | 0.36 |
| ▸ | GBA2 | Q9HCG7 | 13/20 | 0.36 |
| ▸ | GBA1 | P04062 | 12/20 | 0.36 |
| ▸ | LCT | P09848 | 8/20 | 0.36 |
| ▸ | SI | P14410 | 6/20 | 0.36 |
| ▸ | MGAM | O43451 | 4/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.34 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3411111 | 1.00 | UGCG (0.36) | UGCGGBA2GBA1LCTSI | |
| SCHEMBL13040212 | 0.89 | L3MBTL1 (0.38) | UGCGGBA2GBA1LCTSI | |
| SCHEMBL13040206 | 0.89 | L3MBTL1 (0.38) | UGCGGBA2GBA1LCTSI | |
| SCHEMBL3408692 | 0.74 | GBA1 (0.39) | UGCGGBA2GBA1LCTSI | |
| SCHEMBL3408814 | 0.74 | GBA1 (0.39) | UGCGGBA2GBA1LCTSI | |
| SCHEMBL8040473 | 0.74 | GPR119 (0.36) | — | |
| SCHEMBL3411574 | 0.74 | ITGB3 (0.35) | UGCGGBA2GBA1LCTSI | |
| SCHEMBL3407057 | 0.74 | ITGB3 (0.35) | UGCGGBA2GBA1LCTSI | |
| SCHEMBL27847181 | 0.66 | EPHX2 (0.42) | UGCGGBA2GBA1EPHX2TEAD3 | |
| SCHEMBL13040204 | 0.66 | L3MBTL1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100280243-A1 | PROCESS FOR PRODUCTION OF 4- (SUBSTITUTED PHENYL) HEXAHYDROPYRIDO [2,1-C] [1,4] OXAZIN-6-ONE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-11-04 | — | — | US | disclosed |
| EP-2226325-A1 | PROCESS FOR PRODUCTION OF 4-(SUBSTITUTED PHENYL)HEXAHYDROPYRIDOÝ2,1-C¨Ý1,4¨OXAZIN-6-ONE | Eisai R&D Management Co., Ltd. (JP) | 2010-09-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280243-A1 | PROCESS FOR PRODUCTION OF 4- (SUBSTITUTED PHENYL) HEXAHYDROPYRIDO [2,1-C] [1,4] OXAZIN-6-ONE | PSEN1, APP, BACE1 | UGCG 654/4885GBA2 582/4885GBA1 212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.